Literature DB >> 20484029

Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.

Georg Feldmann1, Anjali Mishra, Seung-Mo Hong, Savita Bisht, Christopher J Strock, Douglas W Ball, Michael Goggins, Anirban Maitra, Barry D Nelkin.   

Abstract

Cyclin-dependent kinase 5 (CDK5), a neuronal kinase that functions in migration, has been found to be activated in some human cancers in which it has been implicated in promoting metastasis. In this study, we investigated the role of CDK5 in pancreatic cancers in which metastatic disease is most common at diagnosis. CDK5 was widely active in pancreatic cancer cells. Functional ablation significantly inhibited invasion, migration, and anchorage-independent growth in vitro, and orthotopic tumor formation and systemic metastases in vivo. CDK5 blockade resulted in the profound inhibition of Ras signaling through its critical effectors RalA and RalB. Conversely, restoring Ral function rescued the effects of CDK5 inhibition in pancreatic cancer cells. Our findings identify CDK5 as a pharmacologically tractable target to degrade Ras signaling in pancreatic cancer. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484029      PMCID: PMC3071300          DOI: 10.1158/0008-5472.CAN-09-1107

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.

Authors:  Samuel C Falsetti; De-an Wang; Hairuo Peng; Dora Carrico; Adrienne D Cox; Channing J Der; Andrew D Hamilton; Saïd M Sebti
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

2.  In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.

Authors:  Savita Bisht; Georg Feldmann; Jan-Bart M Koorstra; Michael Mullendore; Hector Alvarez; Collins Karikari; Michelle A Rudek; Carlton K Lee; Amarnath Maitra; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

3.  PDK1 mediates growth factor-induced Ral-GEF activation by a kinase-independent mechanism.

Authors:  Xuejun Tian; Gabriel Rusanescu; Weimin Hou; Brian Schaffhausen; Larry A Feig
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

Review 4.  Reprogramming metastatic tumour cells with embryonic microenvironments.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jennifer Kasemeier-Kulesa; Paul M Kulesa; Lynne-Marie Postovit
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

Review 5.  A decade of CDK5.

Authors:  R Dhavan; L H Tsai
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

6.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

Review 7.  Pancreatic cancer.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

8.  Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Authors:  Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; Hirohiko Kamiyama; Antonio Jimeno; Seung-Mo Hong; Baojin Fu; Ming-Tseh Lin; Eric S Calhoun; Mihoko Kamiyama; Kimberly Walter; Tatiana Nikolskaya; Yuri Nikolsky; James Hartigan; Douglas R Smith; Manuel Hidalgo; Steven D Leach; Alison P Klein; Elizabeth M Jaffee; Michael Goggins; Anirban Maitra; Christine Iacobuzio-Donahue; James R Eshleman; Scott E Kern; Ralph H Hruban; Rachel Karchin; Nickolas Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.

Authors:  Michael E Mullendore; Jan-Bart Koorstra; Yue-Ming Li; G Johan Offerhaus; Xing Fan; Clark M Henderson; William Matsui; Charles G Eberhart; Anirban Maitra; Georg Feldmann
Journal:  Clin Cancer Res       Date:  2009-03-03       Impact factor: 12.531

10.  Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases.

Authors:  Ryutaro Shirakawa; Shuya Fukai; Mitsunori Kawato; Tomohito Higashi; Hirokazu Kondo; Tomoyuki Ikeda; Ei Nakayama; Katsuya Okawa; Osamu Nureki; Takeshi Kimura; Toru Kita; Hisanori Horiuchi
Journal:  J Biol Chem       Date:  2009-06-11       Impact factor: 5.157

View more
  87 in total

Review 1.  Tks adaptor proteins at a glance.

Authors:  Priyanka Saini; Sara A Courtneidge
Journal:  J Cell Sci       Date:  2018-01-08       Impact factor: 5.285

2.  Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.

Authors:  Chaoxin Hu; Tikva Dadon; Venugopal Chenna; Shinichi Yabuuchi; Rajat Bannerji; Robert Booher; Peter Strack; Nilofer Azad; Barry D Nelkin; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2015-04-30       Impact factor: 6.261

3.  Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.

Authors:  John P Eggers; Paul M Grandgenett; Eric C Collisson; Michelle E Lewallen; Jarrod Tremayne; Pankaj K Singh; Benjamin J Swanson; Judy M Andersen; Thomas C Caffrey; Robin R High; Michel Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2011-08-08       Impact factor: 12.531

4.  Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.

Authors:  Arindam Chatterjee; Stephen J Cutler; Robert J Doerksen; Ikhlas A Khan; John S Williamson
Journal:  Bioorg Med Chem       Date:  2014-09-28       Impact factor: 3.641

5.  Quantum capacitance-limited MoS2 biosensors enable remote label-free enzyme measurements.

Authors:  Son T Le; Nicholas B Guros; Robert C Bruce; Antonio Cardone; Niranjana D Amin; Siyuan Zhang; Jeffery B Klauda; Harish C Pant; Curt A Richter; Arvind Balijepalli
Journal:  Nanoscale       Date:  2019-08-13       Impact factor: 7.790

6.  Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.

Authors:  David Askew; Tej K Pareek; Saada Eid; Sudipto Ganguly; Megan Tyler; Alex Y Huang; John J Letterio; Kenneth R Cooke
Journal:  Blood       Date:  2016-11-14       Impact factor: 22.113

7.  Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration.

Authors:  Shuangbing Xu; Xu Li; Zihua Gong; Wenqi Wang; Yujing Li; Binoj Chandrasekharan Nair; Hailong Piao; Kunyu Yang; Gang Wu; Junjie Chen
Journal:  Mol Cell Proteomics       Date:  2014-08-05       Impact factor: 5.911

8.  Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration-proliferation dichotomy.

Authors:  Deepali Bhandari; Inmaculada Lopez-Sanchez; Andrew To; I-Chung Lo; Nicolas Aznar; Anthony Leyme; Vijay Gupta; Ingrid Niesman; Adam L Maddox; Mikel Garcia-Marcos; Marilyn G Farquhar; Pradipta Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-18       Impact factor: 11.205

9.  Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.

Authors:  Wei Wang; Xiaoning Cao; Xiaolei Zhu; Yongliang Gu
Journal:  J Mol Model       Date:  2013-03-23       Impact factor: 1.810

10.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.

Authors:  R Dixon Dorand; Joseph Nthale; Jay T Myers; Deborah S Barkauskas; Stefanie Avril; Steven M Chirieleison; Tej K Pareek; Derek W Abbott; Duncan S Stearns; John J Letterio; Alex Y Huang; Agne Petrosiute
Journal:  Science       Date:  2016-07-21       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.